

MEDIA NOTIFICATION CONTACT: CHRISTOPHER LALLI

CLALLI@AMGEN.COM | 650-457-3204

AMGEN FOUNDATION TO DONATE \$500,000 TO THE SILICON VALLEY COMMUNITY FOUNDATION COVID-19 RESPONSE FUNDS

SOUTH SAN FRANCISCO, Calif., April 10, 2020 -- Amgen and the Amgen Foundation announced on March 23, 2020, an initial commitment of up to \$12.5 million to support U.S. and global relief efforts to address critical needs in communities impacted by the COVID-19 pandemic. The funds will support emergency response efforts in Amgen's U.S. and international communities, patient-focused organizations that are mounting their own response efforts, and international relief efforts by Direct Relief and International Medical Corps.

The Amgen Foundation will also match donations made by Amgen staff around the globe who wish to contribute their own funds to the relief efforts.

"Amgen and the Amgen Foundation are committed to supporting our local Northern California communities in any way that we can during this unprecedented time," said Flavius Martin, Vice President R&D, Oncology & Inflammation, and Site Head. "We are proud to deliver scientific expertise to help address COVID-19, as well as provide financial support for our local counties as they address the Bay Area's most vulnerable during this challenging time."

From this commitment, \$500,000 will be going to Silicon Valley Community Foundation (SVCF), which is leading multiple efforts with Bay Area philanthropic, government, and corporate partners to support those most affected by COVID-19. These responses include:

- The COVID-19 Regional Response Fund, providing support for lowincome individuals and families who face severe financial hardships caused by COVID-19;
- The Regional Nonprofit Emergency Fund, supporting organizations whose operations have been impacted by COVID-19; and
- The Small Business Relief Fund, providing immediate support to struggling self-employed and small business owners.

From Nicole Taylor, President & CEO, Silicon Valley Community Foundation:

"We are grateful for Amgen's generous contribution to our COVID-19 response funds, which will directly support families, nonprofit organizations and small businesses across the Bay Area that are facing incredible hardships during this crisis. We commend our corporate partners for not only standing up to the global threat of COVID-19, but also committing themselves to helping our communities



by taking localized action," said Nicole Taylor, President & CEO, Silicon Valley Community Foundation.

In 2004, Amgen established its presence in South San Francisco, which is now home to the company's largest research and development facility outside of the company's Thousand Oaks headquarters. In the Bay Area, Amgen scientists are focused on discovery research in cardiometabolic disease, oncology and inflammation, and clinical biomarkers and diagnostics. Amgen is a strong supporter of the communities in which its staff members work and live. In Northern California, Amgen and its philanthropic arm, the Amgen Foundation, support science education and community programs, and also established a postdoctoral program in 2014.

About the Amgen Foundation

The Amgen Foundation seeks to advance excellence in science education to inspire the next generation of innovators and invest in strengthening communities where Amgen staff members live and work. To date, the Foundation has donated over \$325 million to local, regional, and international non-profit organizations that impact society in inspiring and innovative ways. The Amgen Foundation brings the excitement of discovery to the scientists of tomorrow through several signature programs, including Amgen Scholars and the Amgen Biotech Experience. For more information, visit AmgenInspires.com and follow us on Twitter @AmgenFoundation.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

###